When combined with abnormal imaging biomarkers (SN echogenicity or Dopamine transporter SPECT), 30% of individuals with PSG confirmed diagnosis of RBD developed a parkinsonian disorder within 2.5 years of follow-up [20]. Here, SLC6A3 is linked to parkinsonian disorder.